肾元颗粒对慢性肾脏病3~5期非透析患者血清成纤维细胞生长因子23、成纤维细胞生长因子受体4、Klotho蛋白的影响
2020-12-23程虹邹新蓉李颖霞王小琴
程虹 邹新蓉 李颖霞 王小琴



[摘要] 目的 觀察肾元颗粒对慢性肾脏病(CKD)3~5期非透析患者的血清成纤维细胞生长因子23(FGF23)、成纤维细胞生长因子受体4(FGFR4)和Klotho蛋白含量的影响,以探讨肾元颗粒对CKD患者血管钙化的可能作用机制。 方法 选取湖北省中医院2018年6月—2019年6月收治的CKD患者60例,按随机数字表法将其分为对照组(28例)和治疗组(32例)。对照组采用尿毒清颗粒治疗,治疗组采用肾元颗粒治疗。连续治疗3个月,观察两组治疗前后生化指标[血清钙、磷、甲状旁腺激素(PTH)及估算的肾小球滤过率(eGFR)]水平及血清FGF23、FGFR4和Klotho蛋白含量。 结果 治疗前,两组钙、磷、PTH、eGFR比较,差异无统计学意义(P > 0.05);治疗后,治疗组血清中磷、PTH含量低于对照组,钙、eGFR高于对照组,差异均有统计学意义(均P < 0.05)。治疗前,两组FGF23、FGFR4、Klotho蛋白含量比较,差异无统计学意义(P > 0.05);治疗后治疗组血清FGF23、Klotho蛋白含量高于对照组,FGFR4含量低与对照组,差异均有统计学意义(均P < 0.05)。 结论 肾元颗粒能够抑制FGF23、FGFR4水平,提高Klotho蛋白含量,这可能是肾元颗粒治疗CKD患者血管钙化作用机制之一。
[关键词] 慢性肾脏病;肾元颗粒;成纤维细胞生长因子23;成纤维细胞生长因子受体4;Klotho蛋白
[中图分类号] R277.5 [文献标识码] A [文章编号] 1673-7210(2020)10(a)-0125-04
Effect of Shenyuan Granules on serum fibroblast growth factor 23, fibroblast growth factor receptor 4 and Klotho protein in non-dialysis patients with chronic kidney disease of stage 3-5
CHENG Hong1,2 ZOU Xinrong1,2 LI Yingxia3 WANG Xiaoqin1,2
1.Department of Nephrology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430061, China; 2.Institute of Nephrology, Hubei Institute of Traditional Chinese Medicine, Hubei Province, Wuhan 430074, China; 3.the First Clinical College, Hubei University of Chinese Medicine, Hubei Province, Wuhan 430061, China
[Abstract] Objective To observe the effect of Shenyuan Granules on the serum fibroblast growth factor 23 (FGF 23), fibroblast growth factor receptor 4 (FGFR 4) and Klotho protein in non-dialysis patients with chronic kidney disease (CKD) of stage 3-5, so as to explore the possible mechanism of Shenyuan Granules on vascular calcification in CKD patients. Methods A total of 60 patients with CKD admitted to Hubei Provincial Hospital of Traditional Chinese Medicine from June 2018 to June 2019 were selected and they were divided into the control group (28 cases) and the treatment group (32 cases) by random number table method. The control group was treated with Niaoduqing Granules, while the treatment group was treated with Shenyuan Granules. After 3 months of continuous treatment, the levels of biochemical indexes (serum calcium, phosphorus, parathyroid hormone [PTH] and estimated glomerular filtration rate [GFR]), and serum FGF23, FGFR4 and Klotho protein content were observed before and after treatment. Results Before treatment, there were no statistically significant differences in calcium, phosphorus, PTH and eGFR between the two groups (P > 0.05). After treatment, serum phosphorus and PTH in the treatment group were lower than those inthe control group, while calcium and eGFR were higher than that in the control group, with statistically significant differences (all P < 0.05). Before treatment, there was no significant difference in FGF23, FGFR4, and Klotho protein content between the two groups (P > 0.05). After treatment, serum FGF23 and Klotho protein content in the treatment group were higher than those in the control group, and FGFR4 content was lower than that in the control group, with statistically significant differences (all P < 0.05). Conclusion Shenyuan Granules can inhibit FGF23 and FGFR4 levels and increase Klotho protein content, which may be one of the mechanisms of Shenyuan Granules in the treatment of vascular calcification in patients with CKD.
[Key words] Chronic kidney disease; Shenyuan Granules; Fibroblast growth factor 23; Fibroblast growth factor receptor 4; Klotho protein
慢性肾脏病(chronic kidney disease,CKD)是指各种原因引起的肾脏的结构或功能异常≥3个月,包括肾脏的形态或病理异常、与肾脏相关的血尿成分异常、肾脏的影像学异常;或不明原因估算的肾小球滤过率(eGFR)下降[<60 mL/(min·1.73m2)]大于或等于3个月。CKD进展会导致终末期肾衰竭、诱发心血管疾病,对患者生命带来威胁[1],全球約10%的人口受到CKD的影响[2]。肥胖、糖尿病、高血压和血脂异常等均是CKD的主要危险因素[3],血管钙化是导致CKD合并心血管疾病(cardiovascular disease,CVD)的重要因素。目前对CKD合并血管钙化的防治方案仍存在诸多不足,开发新的治疗干预措施将会减少全世界面临CKD的风险[4]。中医药在延缓CKD向终末期肾脏病发展,治疗并发症,改善患者生活质量方面起着重要作用[5]。
尿毒清颗粒是治疗CKD的常用中成药,在CKD的临床治疗中发挥了重要作用[6]。肾元颗粒是湖北省中医院(以下简称“我院”)肾病科在大量临床治疗中积累的经验方,可改善患者肾功能、提高患者生活质量,与中药辨证口服方比较,具有更明显的效果[7]。本研……
